Evidence that the strategy is more important than the agent to treat rheumatoid arthritis: Data from clinical trials of combinations of non-biologic dmards, with Protocol-Driven intensification of therapy for tight control or Treat-To-Target

Bulletin of the Hospital for Joint Diseases

Volumn 71, Issue , 2013, Pages S33-S40

  Pincus, Theodore ^a   Castrejón, Isabel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE;

ARTICLE; CLINICAL TRIAL; DAS28; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; INFORMATION PROCESSING; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; REMISSION INDUCTION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84888321983     PISSN: 23284633     EISSN: 23285273     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arthritis Rheum. 2003 Jun;48(6):1481-3.
2. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med. 1983 Oct;99(4):544-50.
3. Freireich EJ. Methods for evaluating response to treatment in adult acute leukemia. Blood Cells. 1983;9(1):5-20.
4. Pincus T, Sokka T. Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am. 2004 Nov;30(4):701-24, v-vi.
5. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010 Jun;69(6):964-75.
6. Pincus T, Cronstein B, Braun J. Methotrexate--the anchor drug--an introduction. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S1-2.
7. Pincus T, Gibson K, Castrejon I. Update on methotrexate as the anchor drug for rheumatoid arthritis (RA). Bull Hosp Jt Dis. 2013;71(Suppl 1):S9-19.
8. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007 Nov;66(11):1491-6.
9. Castrejon I, Gibson K, Pincus T. Efficacy and safety of methotrexate in combination with other non-biologic diseasemodifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. Bull Hosp Jt Dis. 2013;71(Suppl 1):S20-8.
10. van der Heijde DM, van ‘t Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993 Mar;20(3):579-81.
11. Prevoo ML, van ‘t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44-8.
12. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430):263-9.
13. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005 Sep;64(9):1294-8.
14. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 Nov;66(11):1443-9.
15. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005 Nov;52(11):3381-90.
16. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008 Jun;67(6):815-22.
17. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008 May;58(5):1310-7.
18. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford). 2008 Jan;47(1):59-64.
19. Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012 Sep;64(9):2824-35.
20. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009 Aug 8;374(9688):430-2.
21. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011 Jun;70(6):1039-46.
22. Verstappen SM, Bakker MF, Heurkens AH, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis. 2010 Jun;69(6):1044-8.
23. Clegg DO, Dietz F, Duffy J, et al. Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol. 1997 Oct;24(10):1896-902.
24. Hetland ML, Østergaard M, Ejbjerg B, et al. Short-and longterm efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis. 2012 Jun;71(6):851-6.
25. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum. 2002 Apr;46(4):913-20.
26. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2009 Mar 15;61(3):291-927.
27. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012 May;64(5):640-7.
28. Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken). 2010 Feb;62(2):181-9.
29. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1-12.